NutriBand Q2 Revenue Falls 30%, Material Weakness in Controls Disclosed
NTRB has more than doubled off its 52-week low of $2.8 on elevated volume (4.3× avg).
Summary
NutriBand reported a 29.7% revenue decline in Q2 FY2027 and disclosed material weaknesses in internal controls, including lack of segregation of duties and reliance on third-party consultants.
Key Events · Earnings and Guidance · NTRB
-
Q2 Revenue Declines 29.7%
Revenue fell to $437,514 from $622,452 a year ago as a principal Pocono Pharmaceuticals customer moved operations to Asia. Six-month revenue declined to $870,913 from $1,289,884.
-
Material Weakness in Internal Controls
Management concluded disclosure controls and procedures are not effective due to absence of segregation of duties, lack of qualified accounting personnel, and excessive reliance on third-party consultants.
-
Cash Burn Continues
Cash declined to $3,421,615 from $4,574,857 at January 31, 2026. Operating activities used $1,148,103 in the first half, though this improved from $2,650,313 a year earlier.
-
Going Concern Assessment
Management believes substantial doubt about going concern is alleviated by the $5 million credit line extended June 1, 2026 and $3.4 million cash on hand, but the company has generated operating losses since inception.
Analysis · NTRB · Industrial Applications And Services
NutriBand's Q2 FY2027 revenue dropped 29.7% year-over-year to $437,514 as a key contract manufacturing customer moved operations to Asia. The company also disclosed that its disclosure controls and procedures are not effective due to material weaknesses including lack of segregation of duties and reliance on third-party consultants. While management believes going concern doubt is alleviated by a $5 million credit line extension and $3.4 million in cash, the company has generated operating losses since inception and used $1.15 million in operating cash flow during the first half. The material weakness disclosure is a governance red flag that warrants investor attention.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1819 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTRB was trading at $5.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $72.6M. The 52-week trading range was $2.80 to $8.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.